Literature DB >> 33625426

Multivariant ligands stabilize anionic solvent-oriented α-CsPbX3 nanocrystals at room temperature.

Yanqing Luo1, Tao Tan1, Sen Wang1, Ran Pang1, Lihong Jiang1, Da Li1, Jing Feng1, Hongjie Zhang1, Su Zhang1, Chengyu Li1.   

Abstract

Cubic phase CsPbX3 nanocrystals (NCs) are promising candidates for optoelectronic applications. However, their chemical stability heavily depends on the dynamic ionic surface. In this work, based on the interdependency of the ligands and the reaction solvent, a protocol is developed for high-quality α-CsPbX3 under ambient conditions. Utilizing this method, the size and full width at half maximum of CsPbX3 NCs can be simply tuned via changing the cationic ligands or reaction solvent, such as CH3Cl, CH2Cl2, or toluene. One remarkable result is the synthesis of cubic CsPbI3 NCs, for which large-scale syntheses have not been reported in the literature except for our method, due to significant phase transition at room temperature. Another result is that we have realized ultrasmall sized CsPbCl3 NCs with emission at 385 nm for the first time. Furthermore, the elimination of reaction solvent (such as ODE, DMSO, DMF) in our protocol reduces the purification-induced surface ligand loss and the irreversible phase transition to a nonfluorescent phase. Our CsPbX3 NCs show near-perfect photoluminescence quantum yield (PL QY) and long-term stability in the presence of moisture. Further characterization demonstrates that all the ligands, whether the initial paired X type or the degenerated hybrid L-X type, remain perfectly passivating on the defect sites throughout.

Entities:  

Year:  2021        PMID: 33625426     DOI: 10.1039/d0nr08697e

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  1 in total

1.  A novel and facile synthesis strategy for highly stable cesium lead halide nanowires.

Authors:  Ranran Zhou; Chi-An Cheng; Siying Qiu; Jiayi Chen; Kun Nie; Mengyun Wu; Panlong Lin; Hua Wang; Luoxin Wang; Lefu Mei
Journal:  RSC Adv       Date:  2021-08-25       Impact factor: 3.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.